Professor Munitta Muthana

School of Medicine and Population Health

School Director of One University

Professor of Immuno-oncology

m.muthana@sheffield.ac.uk
+44 114 215 9057

D Floor, The Medical School

Full contact details

Professor Munitta Muthana
School of Medicine and Population Health
D Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk

I joined the University of Sheffield in 2002 as a post-doctoral scientist in the Immunobiology Research Unit. From 2005 I held a research position in the Tumour Targeting Group where I was awarded funding as an independent researcher from the Prostate Cancer Charity (2007) and the Medical Research Council (2010). In 2011, I was appointed as non-clinical lecturer and I am now Senior Lecturer in the Department of Oncology and Metabolism.

Current PhD opportunities:

Research interests

Our tea. ‘Nanobug Oncology Sheffield’ (@Nanobug_Shef) focuses on developing state-of-the-art methods to target anticancer therapies to tumours. For example, we have devised a way to use macrophages as ‘trojans’ to deliver large quantities of cancer-killing virus to both primary and secondary tumours simultaneously (click here). We are currently developing innovative nanomedicine platforms to improve the targeting of drugs to tumours so that healthy tissue remains unharmed. We have used these platforms to protect and deliver oncolytic viruses via the bloodstream so that advanced metastatic cancers can be treated. These include liposomes, nanohydrogels, silk fibroin, extracellular vesicles, and magnetic nanoparticles. For the latter, we recently demonstrated that iron particles purified from magnetotactic bacteria were able to shield viruses and guide them to tumours in models of breast cancer. https://www.theguardian.com/science/2022/may/08/magnets-made-by-soil-bacteria-offer-hope-for-breast-and-prostate-cancer

Current projects

Targeting novel oncolytic viruses to tumours.
Using nanomagnet technology to improve tumour targeting.
Developing novel magnetic devices for cancer.
Using a novel microfluidic device for producing silk fibroin nanoparticles.
Developing nanoplatforms for targeting oncolytic viruses.
Characterisation of infiltrating subsets of monocytes/macrophages in the tumour microenvironment.
Using immune checkpoint inhibitors in combination with oncolytic viruses.

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Howard FHN, Al‐Janabi H, Patel P, Cox K, Smith E, Vadakekolathu J, Pockley AG, Conner J, Nohl JF, Allwood DA , Collado‐Rojas C et al (2022) Nanobugs as drugs: bacterial derived nanomagnets enhance tumor targeting and oncolytic activity of HSV‐1 virus. Small. View this article in WRRO
Kim T, Johnston J, Castillo-Lluva S, Cimas FJ, Hamby S, Gonzalez-Moreno S, Villarejo-Campos P, Goodall AH, Velasco G, Ocana A , Muthana M et al (2022) TRIB1 regulates tumor growth via controlling tumor-associated macrophage phenotypes and is associated with breast cancer survival and treatment response. Theranostics, 12(8), 3584-3600.
Iscaro A, Jones C, Forbes N, Mughal A, Howard FN, Janabi HA, Demiral S, Perrie Y, Essand M, Weglarz A , Cruz LJ et al (2022) Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus. Nanomedicine: Nanotechnology, Biology and Medicine, 40. View this article in WRRO
Canuas-Landero VG, George CN, Lefley DV, Corness H, Muthana M, Wilson C & Ottewell PD (2021) Oestradiol contributes to differential antitumour effects of adjuvant zoledronic acid observed between pre- and post-menopausal women. Frontiers in Endocrinology, 12. View this article in WRRO
Kwan A, Winder N & Muthana M (2021) Oncolytic virotherapy treatment of breast cancer : barriers and recent advances. Viruses, 13(6). View this article in WRRO
Müller LME, Migneco G, Scott GB, Down J, King S, Askar B, Jennings V, Oyajobi B, Scott K, West E , Ralph C et al (2021) Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9(3). View this article in WRRO
Sier VQ, de Vries MR, van der Vorst JR, Vahrmeijer AL, van Kooten C, Cruz LJ, de Geus-Oei L-F, Ferreira V, Sier CFM, Alves F & Muthana M (2021) Cell-based tracers as Trojan horses for image-guided surgery. International Journal of Molecular Sciences, 22(2). View this article in WRRO
Iscaro A, Howard NF & Muthana M (2019) Nanoparticles: properties and applications in cancer immunotherapy. Current Pharmaceutical Design, 25(17), 1962-1979.
Song W, Gregory DA, Al-janabi H, Muthana M, Cai Z & Zhao X (2019) Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer cells. International Journal of Pharmaceutics, 555, 322-336. View this article in WRRO
Song W, Muthana M, Mukherjee J, Falconer RJ, Biggs CA & Zhao X (2017) Magnetic-Silk Core–Shell Nanoparticles as Potential Carriers for Targeted Delivery of Curcumin into Human Breast Cancer Cells. ACS Biomaterials Science & Engineering, 3(6), 1027-1038. View this article in WRRO
Muthana M, Hawtree S, Wilshaw A, Linehan E, Roberts H, Khetan S, Adeleke G, Wright F, Akil M, Fearon U , Veale D et al (2015) C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis. Proceedings of the National Academy of Sciences, 112(37), 11618-11623. View this article in WRRO
Muthana M, Kennerley AJ, Hughes R, Faganano E, Richardson J, Paul M, Murdoch C, Wright F, Payne C, Lythgoe MF , Farrow N et al (2015) Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting. Nature Communications, 6(-), ---. View this article in WRRO
Murdoch C, Tazzyman S, Harrison J, Yeomans J & Muthana M () Macrophage-mediated response to hypoxia in disease. Hypoxia, 185-185. View this article in WRRO

Conference proceedings papers

Muthana M, Khetan S, Hawtree S, Davies H, Gbadebo A, Akil M, Ciani B, Wright F & Wilson AG (2014) 233. Biological Roles of C5ORF30 in Rheumatoid Arthritis Synovial Fibroblasts. Rheumatology, Vol. 53(suppl_1) (pp i147-i147)

All publications

Journal articles

Al-janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, de Bono J, Nunns H, Bailey C , Junker-Jensen A et al (2024) Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer, 12(7), e009368-e009368.
Rahman MM, Wells G, Rantala JK, Helleday T, Muthana M & Danson SJ (2024) In-vitro assays for immuno-oncology drug efficacy assessment and screening for personalized cancer therapy: scopes and challenges. Expert Review of Clinical Immunology. View this article in WRRO
Kwan A, Stark K, Allen R, Ottewell P & Muthana M (2024) An Overview of the Bench to Bedside Models of Breast Cancer in the Era of Cancer Immunotherapy. Medical Research Archives, 12(6).
Hapuarachi B, Danson S, Wadsley J & Muthana M (2023) Exercise to transform tumours from cold to hot and improve immunotherapy responsiveness. Frontiers in Immunology, 14, 1335256.
Egerton K, Mitchell TA, Gravells P, Katse R, Fisher M, Muthana M, Eyers CE, Eyers PA & Bryant HE (2023) 18P AURKB inhibition radiosensitises NSCLC by altering mitotic fate. ESMO Open, 8(1), 101664-101664.
Patel P, Alghamdi A, Shaw G, Legge C, Glover M, Freeman D, Hodgetts H, Wilson E, Howard F, Staniland S , Kennerley AJ et al (2023) Development of a personalised device for systemic magnetic drug targeting to brain tumours. Nanotheranostics, 7(1), 102-116.
Winder N, Gohar S & Muthana M (2022) Norovirus: an overview of virology and preventative measures. Viruses, 14(12).
Howard FHN, Al‐Janabi H, Patel P, Cox K, Smith E, Vadakekolathu J, Pockley AG, Conner J, Nohl JF, Allwood DA , Collado‐Rojas C et al (2022) Nanobugs as drugs: bacterial derived nanomagnets enhance tumor targeting and oncolytic activity of HSV‐1 virus. Small. View this article in WRRO
Kim T, Johnston J, Castillo-Lluva S, Cimas FJ, Hamby S, Gonzalez-Moreno S, Villarejo-Campos P, Goodall AH, Velasco G, Ocana A , Muthana M et al (2022) TRIB1 regulates tumor growth via controlling tumor-associated macrophage phenotypes and is associated with breast cancer survival and treatment response. Theranostics, 12(8), 3584-3600.
Iscaro A, Jones C, Forbes N, Mughal A, Howard FN, Janabi HA, Demiral S, Perrie Y, Essand M, Weglarz A , Cruz LJ et al (2022) Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus. Nanomedicine: Nanotechnology, Biology and Medicine, 40. View this article in WRRO
Canuas-Landero VG, George CN, Lefley DV, Corness H, Muthana M, Wilson C & Ottewell PD (2021) Oestradiol contributes to differential antitumour effects of adjuvant zoledronic acid observed between pre- and post-menopausal women. Frontiers in Endocrinology, 12. View this article in WRRO
Kwan A, Winder N & Muthana M (2021) Oncolytic virotherapy treatment of breast cancer : barriers and recent advances. Viruses, 13(6). View this article in WRRO
George C, Lefley D, Canuas-Landero V, Tulotta C, Corness H, Wilson C, Muthana M & Ottewell P (2021) Differential effects of zoledronic acid and oestrogen on anti-cancer immunity. Bone Reports, 14, 101024.
Taher Z, Legge C, Winder N, Lysyganicz P, Rawlings A, Bryant H, Muthana M & Staniland S (2021) Magnetosomes and magnetosome mimics : preparation, cancer cell uptake and functionalization for future cancer therapies. Pharmaceutics, 13(3).
Müller LME, Migneco G, Scott GB, Down J, King S, Askar B, Jennings V, Oyajobi B, Scott K, West E , Ralph C et al (2021) Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9(3). View this article in WRRO
Deng S, Iscaro A, Zambito G, Mijiti Y, Minicucci M, Essand M, Lowik C, Muthana M, Censi R, Mezzanotte L & Di Martino P (2021) Development of a new hyaluronic acid based redox-responsive nanohydrogel for the encapsulation of oncolytic viruses for cancer immunotherapy. Nanomaterials, 11(1).
Sier VQ, de Vries MR, van der Vorst JR, Vahrmeijer AL, van Kooten C, Cruz LJ, de Geus-Oei L-F, Ferreira V, Sier CFM, Alves F & Muthana M (2021) Cell-based tracers as Trojan horses for image-guided surgery. International Journal of Molecular Sciences, 22(2). View this article in WRRO
Aldughaim MS, Muthana M, Alsaffar F & Barker MD (2021) Specific targeting of PEGylated liposomal doxorubicin (Doxil®) to tumour cells using a novel TIMP3 peptide. Molecules, 26(1).
George CN, Canuas-Landero V, Theodoulou E, Muthana M, Wilson C & Ottewell P (2020) Oestrogen and zoledronic acid driven changes to the bone and immune environments: potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions. Journal of Bone Oncology, 25.
Howard F & Muthana M (2020) Designer nanocarriers for navigating the systemic delivery of oncolytic viruses. Nanomedicine, 15(1), 93-110.
Niespolo C, Shologu Z, Satam S, Iscaro A, Muthana M, Socorro S, Wilson HL & Kiss-Toth E (2019) microRNAs regulating Tribbles-1: potential molecular targets in prostate cancer. European Urology Supplements, 18(8), e3090-e3091.
Narayanan P, Martinez Campesino L, Kim T, Muthana M, Wilson HL & Kiss-Toth E (2019) Macrophage-associated changes in peri-prostatic adipose tissue; a novel local driver of prostate tumorigenesis?. European Urology Supplements, 18(8), e3060-e3060.
Iscaro A, Howard NF & Muthana M (2019) Nanoparticles: properties and applications in cancer immunotherapy. Current Pharmaceutical Design, 25(17), 1962-1979.
Dorris ER, Tazzyman SJ, Moylett J, Ramamoorthi N, Hackney J, Townsend M, Muthana M, Lewis MJ, Pitzalis C & Wilson AG (2019) The Autoimmune Susceptibility Gene C5orf30 Regulates Macrophage-Mediated Resolution of Inflammation. The Journal of Immunology, 202(4), 1069-1078.
Song W, Gregory DA, Al-janabi H, Muthana M, Cai Z & Zhao X (2019) Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer cells. International Journal of Pharmaceutics, 555, 322-336. View this article in WRRO
Stewart GR, Tazzyman S, Lath D, Down J, Snowden JA, Lawson M, Muthana M & Chantry AD (2018) Myeloma-Specific Oncolytic Adenovirus Induces Significant Tumour Oncolysis In Vitro and In Vivo and Prevents Cell Line Regrowth. Blood, 132(Supplement 1), 3213-3213.
Song W, Muthana M, Mukherjee J, Falconer RJ, Biggs CA & Zhao X (2017) Magnetic-Silk Core–Shell Nanoparticles as Potential Carriers for Targeted Delivery of Curcumin into Human Breast Cancer Cells. ACS Biomaterials Science & Engineering, 3(6), 1027-1038. View this article in WRRO
Rahat MA, Coffelt SB, Granot Z, Muthana M & Amedei A (2016) Macrophages and Neutrophils: Regulation of the Inflammatory Microenvironment in Autoimmunity and Cancer.. Mediators Inflamm, 2016, 5894347-5894347. View this article in WRRO
Colley HE, Muthana M, Danson SJ, Jackson LV, Brett ML, Harrison J, Coole SF, Mason DP, Jennings LR, Wong M , Tulasi V et al (2015) An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. Journal of Medicinal Chemistry, 58(23), 9309-9333. View this article in WRRO
Hawtree S, Muthana M, Wilkinson JM, Akil M & Wilson AG (2015) Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis. Human Molecular Genetics, 24(19), 5367-5377. View this article in WRRO
Muthana M, Hawtree S, Wilshaw A, Linehan E, Roberts H, Khetan S, Adeleke G, Wright F, Akil M, Fearon U , Veale D et al (2015) C5orf30 is a negative regulator of tissue damage in rheumatoid arthritis. Proceedings of the National Academy of Sciences, 112(37), 11618-11623. View this article in WRRO
Hughes R, Qian B-Z, Rowan C, Muthana M, Keklikoglou I, Olson OC, Tazzyman S, Danson S, Addison C, Clemons M , Gonzalez-Angulo AM et al (2015) Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Research, 75(17), 3479-3491.
Muthana M, Kennerley AJ, Hughes R, Faganano E, Richardson J, Paul M, Murdoch C, Wright F, Payne C, Lythgoe MF , Farrow N et al (2015) Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting. Nature Communications, 6(-), ---. View this article in WRRO
Hawtree S, Muthana M, Wilkinson JM & Wilson AG (2014) 79. Investigation of the Role of Histone Deacetylases in Rheumatoid Arthritis Synovial Fibroblasts. Rheumatology, 53(suppl_1), i85-i85.
Ellam T, Hameed A, ul Haque R, Muthana M, Wilkie M, Francis SE & Chico TJA (2014) Vitamin D deficiency and exogenous vitamin D excess similarly increase diffuse atherosclerotic calcification in apolipoprotein E knockout mice.. PLoS One, 9(2), e88767. View this article in WRRO
Chen Y-Y, Brown NJ, Jones R, Lewis CE, Mujamammi AH, Muthana M, Seed MP & Barker MD (2014) A peptide derived from TIMP-3 inhibits multiple angiogenic growth factor receptors and tumour growth and inflammatory arthritis in mice.. Angiogenesis, 17(1), 207-219. View this article in WRRO
Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) THU0004 The Role of Histone Deacetylases in Rheumatoid Arthritis Fibroblasts-Like Synoviocytes. Annals of the Rheumatic Diseases, 72(Suppl 3), A165.4-A166.
Hardy WJ, Aynsley S, Fearon U, Veale D, Wilson AG & Muthana M (2013) THU0107 Hypoxia-Inducible Factor 2A is Preferentially Expressed by M2-Like Synovial Macrophages in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 72(Suppl 3), A199.1-A199.
Albloui FS, Muthana M, Wilson AG & Grabowski PS (2013) AB0087 Tissue localisation of acid sensing proteins in synovial biopsies from patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 72(Suppl 3), A812.2-A812.
Hardy WJ, Aynsley S, Fearon U, Veale D, Wilson AG & Muthana M (2013) HYPDXIA-INDUCIBLE FACTOR 2A IS PREFERENTIALLY EXPRESSED BY M2-LIKE SYNOVIAL MACROPHAGES IN RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES, 72, 199-199.
Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS FIBROBLASTS-LIKE SYNOVIOCYTES. ANNALS OF THE RHEUMATIC DISEASES, 72, 165-166.
Hawtree S, Muthana M & Wilson AG (2013) The role of histone deacetylases in rheumatoid arthritis fibroblast-like synoviocytes.. Biochem Soc Trans, 41(3), 783-788.
Mehta P, Holder S, Fisher B, Vincent T, Nadesalingam K, Maciver H, Shingler W, Bakshi J, Hassan S, D'Cruz D , Chan A et al (2013) Case Reports * 1. A Late Presentation of Loeys-Dietz Syndrome: Beware of TGF Receptor Mutations in Benign Joint Hypermobility. Rheumatology, 52(suppl 1), i56-i94.
Fleischmann R, van Vollenhoven RF, Smolen J, Emery P, Florentinus S, Rathmann S, Kupper H, Kavanaugh A, Taylor P, Genovese M , Keystone EC et al (2013) Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach. Rheumatology, 52(suppl 1), i44-i55.
Muthana M, Richardson J, Rodrigues S & Lewis C (2013) Construction of Human Monocyte Derived Macrophages Armed with Oncolytic Viruses. BIO-PROTOCOL, 3(13).
Muthana M, Rodrigues S, Chen Y-Y, Welford A, Hughes R, Tazzyman S, Essand M, Morrow F & Lewis CE (2013) Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation.. Cancer Res, 73(2), 490-495.
Murdoch C, Aziz HA, Fang H-Y, Jezan H, Musaid R & Muthana M (2011) Khat (Catha edulis) alters the phenotype and anti-microbial activity of peripheral blood mononuclear cells.. J Ethnopharmacol, 138(3), 780-787.
Coffelt SB, Chen Y-Y, Muthana M, Welford AF, Tal AO, Scholz A, Plate KH, Reiss Y, Murdoch C, De Palma M & Lewis CE (2011) Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion.. J Immunol, 186(7), 4183-4190.
Owen MR, Stamper IJ, Muthana M, Richardson GW, Dobson J, Lewis CE & Byrne HM (2011) Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy.. Cancer Res, 71(8), 2826-2837.
Muthana M, Giannoudis A, Scott SD, Fang H-Y, Coffelt SB, Morrow FJ, Murdoch C, Burton J, Cross N, Burke B , Mistry R et al (2011) Use of macrophages to target therapeutic adenovirus to human prostate tumors.. Cancer Res, 71(5), 1805-1815.
Muthana M, Multhoff G & Pockley AG (2010) Tumour infiltrating host cells and their significance for hyperthermia.. Int J Hyperthermia, 26(3), 247-255.
Murdoch C, Muthana M, Coffelt SB & Lewis CE (2008) The role of myeloid cells in the promotion of tumour angiogenesis.. Nat Rev Cancer, 8(8), 618-631.
Muthana M, Scott SD, Farrow N, Morrow F, Murdoch C, Grubb S, Brown N, Dobson J & Lewis CE (2008) A novel magnetic approach to enhance the efficacy of cell-based gene therapies.. Gene Ther, 15(12), 902-910.
Pockley AG, Muthana M & Calderwood SK (2008) The dual immunoregulatory roles of stress proteins.. Trends Biochem Sci, 33(2), 71-79.
Pockley AG, Fairburn B, Mirza S, Slack LK, Hopkinson K & Muthana M (2007) A non-receptor-mediated mechanism for internalization of molecular chaperones.. Methods, 43(3), 238-244.
Slack LK, Muthana M, Hopkinson K, Suvarna SK, Espigares E, Mirza S, Fairburn B & Pockley AG (2007) Administration of the stress protein gp96 prolongs rat cardiac allograft survival, modifies rejection-associated inflammatory events, and induces a state of peripheral T-cell hyporesponsiveness.. Cell Stress Chaperones, 12(1), 71-82.
Fairburn B, Muthana M, Hopkinson K, Slack LK, Mirza S, Georgiou AS, Espigares E, Wong C & Pockley AG (2006) Analysis of purified gp96 preparations from rat and mouse livers using 2-D gel electrophoresis and tandem mass spectrometry.. Biochimie, 88(9), 1165-1174.
Mirza S, Muthana M, Fairburn B, Slack LK, Hopkinson K & Pockley AG (2006) The stress protein gp96 is not an activator of resting rat bone marrow-derived dendritic cells, but is a costimulator and activator of CD3+ T cells.. Cell Stress Chaperones, 11(4), 364-378.
Muthana M, Fairburn B, Mirza S, Slack LK, Hopkinson K & Pockley AG (2006) Identification of a rat bone marrow-derived dendritic cell population which secretes both IL-10 and IL-12: evidence against a reciprocal relationship between IL-10 and IL-12 secretion.. Immunobiology, 211(5), 391-402.
Muthana M, Slack LK, Hopkinson K, Espigares E, Fairburn B, Mirza S & Pockley AG (2005) Gp96 prolongs rat cardiac allograft survival and modifies rejection-associated inflammatory events. IMMUNOLOGY, 116, 107-107.
Mirza S, Muthana M, Slack LK, Hopkinson K, Fairburn B & Pockley AG (2005) The stress protein gp96 does not activate rat bone marrow-derived dendritic cells. IMMUNOLOGY, 116, 98-98.
Murdoch C, Muthana M & Lewis CE (2005) Hypoxia regulates macrophage functions in inflammation.. J Immunol, 175(10), 6257-6263.
Pockley AG & Muthana M (2005) Heat shock proteins and allograft rejection.. Contrib Nephrol, 148, 122-134.
Muthana M, Fairburn B, Mirza S, Slack LK & Pockley AG (2004) Systematic evaluation of the conditions required for the generation of immature rat bone marrow-derived dendritic cells and their phenotypic and functional characterization.. J Immunol Methods, 294(1-2), 165-179.
Carlring J, Shaif-Muthana M, Sisley K, Rennie IG & Murray AK (2003) Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses.. Immunology, 109(1), 41-48.
Molife R, Muthana M, Wilkinson D, Hedley S, Browne S, Brookes R, Murray A, Rennie I & Lorigan P (2002) Pilot study: Immunisation with melanoma associated peptides and GM-CSF in HLA-A2 patients with metastatic melanoma.. BRIT J CANCER, 86, S115-S115.
Shaif-Muthana M, McIntyre C, Sisley K, Rennie I & Murray A (2000) Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells.. Cancer Res, 60(22), 6441-6447.
Stewart G, Tazzyman S, Sun Y, Andrews RE, Harrison J, Lath D, Down J, Robinson G, Wang X, Muthana M , Chantry AD et al () An oncolytic adenovirus targeting SLAMF7 demonstrates anti-myeloma efficacy. Leukemia.
Gao Z, Mansor MH, Howard F, MacInnes J, Zhao X & Muthana M () Microfluidic-Assisted Silk Nanoparticles Co-Loaded with Epirubicin and Copper Sulphide: A Synergistic Photothermal–Photodynamic Chemotherapy Against Breast Cancer. Nanomaterials, 15(3), 221-221.
Mansor MH, Gao Z, Howard F, MacInnes J, Zhao X & Muthana M () Efficient and Rapid Microfluidics Production of Bio-Inspired Nanoparticles Derived from Bombyx mori Silkworm for Enhanced Breast Cancer Treatment. Pharmaceutics, 17(1), 95-95.
Kwan A, Mcdermott-Brown I & Muthana M () Proliferating Cell Nuclear Antigen in the Era of Oncolytic Virotherapy. Viruses, 16(8), 1264-1264.
Gao Z, Mansor MH, Winder N, Demiral S, Maclnnes J, Zhao X & Muthana M () Microfluidic-Assisted ZIF-Silk-Polydopamine Nanoparticles as Promising Drug Carriers for Breast Cancer Therapy. Pharmaceutics, 15(7), 1811-1811.
Winder N, Ashraf Z, Gohar S, Baalbaki N, Cork M, Danby S & Muthana M () Are mild cleansers appropriate for hand hygiene in the COVID era? An in vitro investigation of the antiviral efficacy of different hand hygiene products. Frontiers in Virology, 3, 1180815.
Tazzyman S, Stewart GR, Yeomans J, Linford A, Lath D, Conner J, Muthana M, Chantry AD & Lawson MA () HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib In Vitro and Significantly Reduces Systemic Tumor Growth in Mouse Models. Viruses, 15(3), 603-603.
Kwan A, Howard F, Winder N, Atkinson E, Jailani A, Patel PB, Allen R, Ottewell PD, Shaw GC, Conner J , Wilson C et al () Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer. Future Pharmacology, 2(4), 444-459.
Howard FHN, Kwan A, Winder N, Mughal A, Collado-Rojas C & Muthana M () Understanding Immune Responses to Viruses—Do Underlying Th1/Th2 Cell Biases Predict Outcome?. Viruses, 14(7), 1493-1493.
Howard F, Conner J, Danson S & Muthana M () Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability. Frontiers in Molecular Biosciences, 9.
Kim T, Johnston J, Felipe FJC, Hamby S, Castillo-Lluva S, Goodall AH, Velasco G, Ocana A, Muthana M & Kiss-Toth E () TRIB1 regulates tumour growth via controlling tumour-associated macrophage phenotypes and is associated with breast cancer survival and treatment response.
Murdoch C, Tazzyman S, Harrison J, Yeomans J & Muthana M () Macrophage-mediated response to hypoxia in disease. Hypoxia, 185-185. View this article in WRRO
Kwan A, Winder NJ, Atkinson E, Al-Janabi HH, Allen RJ, Hughes R, Moamin MR, Louie R, Evans D, Hutchinson M , Capper DT et al () Macrophages Mediate the Anti-Tumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. Molecular Cancer Therapeutics, molcanther.0748.2020-molcanther.0748.2020.

Chapters

Nutter Howard FH, Iscaro A & Muthana M (2022) Oncolytic viral particle delivery, Systemic Drug Delivery Strategies (pp. 211-230). Elsevier
Hughes R & Muthana M (2014) The tumor microenvironment: The role of tumor-associated macrophages in cancer progression and responses to therapy, Tumor Immunology and Immunotherapy (pp. 43-62). Oxford University Press
Hughes R, Fang H-Y, Muthana M & Lewis CE (2011) Role of Tumour-Associated Macrophages in the Regulation of Angiogenesis, Tumour-Associated Macrophages (pp. 17-29). Springer New York
Pockley AG & Muthana M (2007) The Pro- and Anti-Inflammatory Properties of the Stress Protein GP96, Heat Shock Proteins: Potent Mediators of Inflammation and Immunity (pp. 309-320). Springer Netherlands
Pockley AG & Muthana M (2007) Immunoregulatory Activities of Extracellular Stress Proteins, Cell Stress Proteins (pp. 377-395). Springer New York
H.N. Howard F, Gao Z, Bin Mansor H, Yang Z & Muthana M () Silk Fibroin Nanoparticles: A Biocompatible Multi-Functional Polymer for Drug Delivery, Biomedical Engineering IntechOpen
Iscaro A, H.N. Howard F, Yang Z, Jenkins F & Muthana M () Perspective Chapter: Liposome Mediated Delivery of Immunotherapeutics for Cancer, Liposomes - Recent Advances, New Perspectives and Applications [Working Title] IntechOpen

Conference proceedings papers

Sheridan K, Doris E, Pimenta M, Falkov J, Fisher M, Muthana M, Shields D, Mains R, Eipper B, Buckley C & Wilson A (2024) Genetically Determined Peptidylglycine Alpha-amidating Monooxygenase (PAM) Mediated Amidation Regulates Tissue Damage by Rheumatoid Arthritis Synovial Fibroblasts. ARTHRITIS & RHEUMATOLOGY, Vol. 76 (pp 1864-1865)
Rahman MM, Wells G, Rantala J, Helleday T, Muthana M & Danson S (2023) 2302P Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays. Annals of Oncology, Vol. 34 (pp S1177-S1177)
Al-janabi H, Pu X, Muthana M, Wang N, Crespo M, Gurel B, De Bono J, Brown JE & Lewis CE (2021) Abstract 2797: Changes in the phenotype of macrophages and CD8+ T Cells in the perivascular niche of prostate tumours following androgen deprivation. Tumor Biology
Al-Janabi H, Pu X, Muthana M, Wang N, Crespo M, Gurel B, De Bono J, Brown JE & Lewis CE (2021) Changes in the phenotype of macrophages and CD8+T Cells in the perivascular niche of prostate tumours following androgen deprivation.. CANCER RESEARCH, Vol. 81(13)
Danson SJ, Conner J, Edwards JG, Blyth KG, Fisher PM, Muthana M, Salawu A, Taylor F, Hodgkinson E, Joyce P , Roman J et al (2020) Oncolytic herpesvirus therapy for mesothelioma – A Phase I/IIa trial of intrapleural administration of HSV1716. Lung Cancer
AL-Janabi H, Conner J, Howard F, Hunt S, Taher Z, Staniland S & Muthana M (2019) Abstract LB-188: Breast cancer immunotherapy using magnetized HSV1716. Immunology
Pu X, AL-Janabi H, Wang N, Muthana M, Brown J & Lewis C (2019) Abstract LB-136: Targeting perivascular macrophages to prevent castration resistance in men with high-risk, localized prostate cancer. Tumor Biology
Pu X, AL-Janabi H, Wang N, Muthana M, Brown J & Lewis C (2019) Abstract LB-136: Targeting perivascular macrophages to prevent castration resistance in men with high-risk, localized prostate cancer. Tumor Biology
Moamin MR, Monk P, Cox A, Ottewell P, Saint-Pol J, Rubinstein E & Muthana M (2019) Abstract LB-036: Tetraspanin 5 expressing macrophages promote mammary tumor growth. Tumor Biology
Moamin MR, Monk P, Cox A, Ottewell P, Saint-Pol J, Rubinstein E & Muthana M (2019) Abstract LB-036: Tetraspanin 5 expressing macrophages promote mammary tumor growth. Tumor Biology
AL-Janabi H, Conner J, Howard F, Hunt S, Taher Z, Staniland S & Muthana M (2019) Abstract LB-188: Breast cancer immunotherapy using magnetized HSV1716. Immunology
Stewart G, Tazzyman ST, Lath D, Down J, Lawson M, Muthana M & Chantry A (2019) Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 185 (pp 97-97)
AL-Janabi H, Conner J, Taher Z, Staniland S & Muthana M (2018) Breast cancer immunotherapy using magnetised oncolytic viruses. European Journal of Cancer, Vol. 92 (pp S4-S4)
Seehra RS, Wharton S, Heath P, Ince P, Muthana M, Garwood C & Simpson J (2018) Hypoxia-induced changes in astrocytes and their role in the formation of age-associated white matter lesions. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, Vol. 44 (pp 17-18)
Dorris E, Creevey K, Moylett J, Tazzyman S, Muthana M & Wilson AG (2017) The Rheumatoid Arthritis Susceptibility Gene C5orf30 Is an Immunomodulator in Macrophages. ARTHRITIS & RHEUMATOLOGY, Vol. 69
Muthana M, Murphy E, Kwan A, Winder N & Conner J (2017) Abstract 2938: Tumour-associated macrophage polarisation and re-education with oncolytic viruses. Tumor Biology
Dorris ER, Creevey K, Moran C, Muthana M & Wilson AG (2016) OP0134 The Rheumatoid Arthritis Susceptibility Gene C5ORF30 Acts as An Immunomodulator in Macrophages. Annals of the Rheumatic Diseases, Vol. 75(Suppl 2) (pp 107.1-107)
Tazzyman S, Muthana M, Harrison J, Lewis C, Conner J & Chantry A (2015) Development of a Trojan horse oncolytic virus for treatment of myeloma.. Journal of Clinical Oncology, Vol. 33(15_suppl) (pp e14035-e14035)
Hardy W, Wright F, Hawtree S, Fearon U, Veale D, Perretti M, Wilson A & Muthana M (2014) OP0296 Hypoxia-Inducible Factor 2A Regulates Macrophage Function in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, Vol. 73(Suppl 2) (pp 174.2-174)
Muthana M, Davies H, Khetan S, Wright F, Hawtree S, Ciani B & Wilson A (2014) THU0515 C5orf30 A Novel Regulator of Tissue Damage in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, Vol. 73(Suppl 2) (pp 361.3-361)
Hawtree S, Muthana M, Wilkinson JM & Wilson AG (2014) FRI0360 Histone Deacetylase One Contributes to the Auto-Aggressive Phenotype of Rheumatoid Arthritis Synovial Fibroblasts. Annals of the Rheumatic Diseases, Vol. 73(Suppl 2) (pp 517.2-517)
Muthana M, Khetan S, Hawtree S, Davies H, Gbadebo A, Akil M, Ciani B, Wright F & Wilson AG (2014) 233. Biological Roles of C5ORF30 in Rheumatoid Arthritis Synovial Fibroblasts. Rheumatology, Vol. 53(suppl_1) (pp i147-i147)
Hawtree S, Muthana M, Wilkinson JM & Wilson AG (2014) INVESTIGATION OF THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 53 (pp 85-85)
Muthana M, Khetan S, Hawtree S, Davies H, Gbadebo A, Akil M, Ciani B, Wright F & Wilson AG (2014) BIOLOGICAL ROLES OF C5ORF30 IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 53 (pp 147-147)
Albloui FS, Muthana M, Wilson AG & Grabowski PS (2014) Acidification enhances acid sensing protein and matrix metalloproteinase expression in human rheumatoid fibroblast like synoviocytes. Annals of the Rheumatic Diseases, Vol. 73(Supplement 2) (pp 511-511)
Davies H, Muthana M, Khetan S, Adeleke G, Hawtree S, Morrow F, Ciani B & Wilson AG (2013) THU0080 The Role of C5ORF30 in Rheumatoid Arthritis Pathogenesis. Annals of the Rheumatic Diseases, Vol. 72(Suppl 3) (pp A190.2-A190)
Muthana M, Davies H, Khetan S, Adeleke G, Hawtree S, Wright F, Ciani B, Akil M & Wilson AG (2013) The biological role of C5orf30 in rheumatoid arthritis pathogenesis. IMMUNOLOGY, Vol. 140 (pp 45-45)
Muthana M, Davies H, Khetan S, Adeleke GA, Hawtree S & Wilson AG (2013) Biological Roles of C5orf30 In Rheumatoid Arthritis Synovial Fibroblasts. ARTHRITIS AND RHEUMATISM, Vol. 65 (pp S1232-S1233)
Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) Investigation Of The Role Of Histone Deacetylases In Rheumatoid Arthritis Synovial Fibroblasts. ARTHRITIS AND RHEUMATISM, Vol. 65 (pp S1035-S1036)
Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) Investigation of the role of histone deacetylases in rheumatoid arthritis synovial fibroblasts. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 94(5) (pp A3-A3)
Albloui FS, Muthana M, Wilson AG & Grabowski PS (2013) TISSUE LOCALISATION OF ACID SENSING PROTEINS IN SYNOVIAL BIOPSIES FROM PATIENTS WITH RHEUMATOID ARTHRITIS. ANNALS OF THE RHEUMATIC DISEASES, Vol. 72 (pp 812-812)
Davies H, Muthana M, Khetan S, Adeleke G, Hawtree S, Morrow F, Ciani B & Wilson AG (2013) THE ROLE OF C5ORF30 IN RHEUMATOID ARTHRITIS PATHOGENESIS. ANNALS OF THE RHEUMATIC DISEASES, Vol. 72 (pp 190-190)
Muthana M, Davies H, Khetan S, Adeleke G, Hawtree S, Tazzyman S, Morrow F, Ciani B & Wilson G (2013) BIOLOGICAL ROLES OF C5ORF30 IN RHEUMATOID ARTHRITIS. RHEUMATOLOGY, Vol. 52 (pp 50-50)
Hawtree S, Muthana M, Aynsley S, Wilkinson JM & Wilson AG (2013) INVESTIGATION OF THE ROLE OF HISTONE DEACETYLASES IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS. RHEUMATOLOGY, Vol. 52 (pp 79-80)
Aynsley S, Hardy J, Veale D, Fearon U, Wilson G & Muthana M (2013) MACROPHAGES IN HYPOXIC RHEUMATOID JOINTS PREFERENTIALLY EXPRESS HYPOXIA-INDUCIBLE TRANSCRIPTION FACTOR-2. RHEUMATOLOGY, Vol. 52 (pp 78-78)
Muthana M, Khetan S, Adeleke GA, Tazzyman S, Aynsley S, Morrow F, Hawtree S, Ciani B & Wilson AG (2012) Biological Roles of C5orf30 in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, Vol. 64(10) (pp S767-S767)
Aynsley S, Fearon U, Wilson AG & Muthana M (2012) Macrophages in Hypoxic Rheumatoid Joints Preferentially Express Hypoxia Inducible Transcription Factor-2. ARTHRITIS AND RHEUMATISM, Vol. 64(10) (pp S767-S767)
Grabowski PS, Muthana M & Wilson AG (2012) Acid sensing protein genes are expressed in human rheumatoid-derived synoviocytes. BONE, Vol. 50 (pp S191-S191)
Khetan S, Muthana M & Wilson AG (2011) C5orf30 a Candidate Susceptibility Gene in Rheumatoid Arthritis. ARTHRITIS AND RHEUMATISM, Vol. 63(10) (pp S719-S719)
Muthana M, Giannoudis A, Scott SD, Mistry R, Murdoch C, Coffelt S, Georgeopolous L, Hamdy F, Brown N, Maitland N & Lewis CE (2010) Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumours. DRUG DISCOVERY TODAY, Vol. 15(23-24) (pp 1097-1098)
Muthana M, Giannoudis A, Scott SD, Mistry R, Murdoch C, Georgeopolous L, Hamdy F, Brown N, Maitland N & Lewis CE (2010) Engineering Macrophages to Synthesize Recombinant Adenoviruses in Hypoxic Areas of Human Prostate Tumours. HUMAN GENE THERAPY, Vol. 21(4) (pp 488-488)
Muthana M, Scott S, Farrow N, Murdoch C & Lewis C (2007) Magnetite nanoparticle-loaded macrophages enhance gene delivery to tumours. IMMUNOLOGY, Vol. 120 (pp 82-82)
Muthana M, Giannoudis A, Scott SD, Burke B, Mistry R, Hamdy F, Brown N, Maitland N & Lewis CE (2006) Engineering macrophages to synthesize recombinant adenoviruses in hypoxic areas of human prostate tumors. CANCER RESEARCH, Vol. 66(8)

Other

Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) Supplementary Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2023) Supplementary Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.

Preprints

Al-janabi H, Moyes K, Allen R, Fisher M, Crespo M, Gurel B, Rescigno P, De Bono J, Nunns H, Bailey C , Juncker-Jensen A et al (2024) Targeting of a STING Agonist to Perivascular Macrophages in Prostate Tumors Delays Resistance to Androgen Deprivation Therapy, Cold Spring Harbor Laboratory.

Teaching interests: I teach Immunology on the MBChB course and I am module lead for Phase 2a immunology. I also deliver the cell-based therapies, Gene Therapy, Animal models in Research and Tumour Immunology lectures for the medical school MSc. Molecular Medicine, MSc. Translational Oncology, MSc. Advanced Cell and Gene therapy, MSc Translational Neuroscience.

Professional activities and memberships

American Association of Cancer Research (AACR).
British Society of Immunology (BSI).
European Macrophage and Dendritic Cell Society and British Society of Immunology.